Aurora Cannabis (ACB) Cash from Restructuring (2018 - 2022)
Aurora Cannabis (ACB) posted quarterly Cash from Restructuring of $2.1 million for Q2 2022, up 753.76% on a QoQ basis from -$327647.8 in Q4 2021.
Aurora Cannabis (ACB) Cash from Restructuring (2018 - 2022) Analysis & Trends
Aurora Cannabis (ACB) has reported Cash from Restructuring for 4 consecutive years, with $2.1 million the latest figure, recorded in Q2 2022.
- Quarterly Cash from Restructuring changed N/A year-over-year to $2.1 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $2.5 million (changed N/A YoY) and the FY2022 annual result came in at $2.2 million, changed N/A from the prior year.
- Cash from Restructuring climbed to $2.1 million in Q2 2022 per ACB's latest filing, from -$327647.8 in the prior quarter.
- Over the last five years, Cash from Restructuring for ACB reached as high as $2.1 million in Q2 2022 and fell as low as -$327647.8 in Q4 2021.
- A 4-year average of $1.1 million and a median of $1.5 million in 2019 frame the typical range for Cash from Restructuring.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 2.14 Mn |
| Dec 31, 2021 | -327,647.80 |
| Sep 30, 2021 | 645,854.77 |
| Mar 31, 2019 | 1.51 Mn |
| Sep 30, 2018 | 1.71 Mn |